文献速递帕金森病与运动障碍

磷左旋多巴/磷卡比多巴:帕金森病皮下治疗新选择

Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
PubMed 文献 · Ann Neurol · 2021-05-04

该研究制备了磷左旋多巴与磷卡比多巴(ABBV-951)的可溶性前体组合,在健康志愿者中皮下输注≤72小时,评估左旋多巴暴露与安全性。结果显示该组合在生理pH附近水溶性高、化学稳定性好,皮下输注可维持稳定的左旋多巴药代动力学特征且耐受性良好。

要点

  • 磷左旋多巴/磷卡比多巴水溶性高、近生理pH化学稳定性好,支持持续皮下输注。
  • 健康志愿者皮下输注后左旋多巴药代动力学特征稳定维持≤72小时,输注耐受性良好。
  • 该结果为口服药物控制不佳的帕金森病患者提供了潜在的新型给药途径。

核心结论

  • 磷左旋多巴/磷卡比多巴可经持续皮下输注稳定递送左旋多巴,支持其进一步开发用于帕金森病治疗。

研究设计与样本

  • 研究制备磷左旋多巴与磷卡比多巴,检测不同pH水介质中的平衡溶解度与化学稳定性。
  • 将pH调节后的冻干材料溶于水制备4:1至20:1比例的磷左旋多巴/磷卡比多巴溶液,在健康志愿者中皮下输注≤72小时。
  • 频繁采集血样测定左旋多巴与卡比多巴暴露,并全程监测安全性。

主要发现

  • 磷左旋多巴/磷卡比多巴(ABBV-951)在近生理pH下具有高水溶性和良好化学稳定性。
  • 皮下输注后左旋多巴药代动力学特征稳定维持≤72小时,输注耐受性良好。

关键数值与推荐

  • 磷左旋多巴/磷卡比多巴溶液比例为4:1至20:1。
  • 健康志愿者皮下输注时间≤72小时。

临床怎么用

  • 对于口服药物控制不佳的帕金森病患者,持续皮下输注磷左旋多巴/磷卡比多巴可能提供稳定的左旋多巴暴露。
  • 该研究为1期临床,支持后续研究,尚需进一步验证疗效与长期安全性。

局限性

  • 研究在健康志愿者中进行,未纳入帕金森病患者。
  • 输注时间≤72小时,缺乏长期安全性与疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug combination effectively delivers stable LD exposure via a minimally invasive and convenient mode and has the potential to treat Parkinson's disease (PD) patients who are not well controlled on oral medication. METHODS: Foslevodopa and foscarbidopa were prepared and the equilibrium solubility and chemical stability examined in aqueous media with different values of pH. Solutions of foslevodopa/foscarbidopa (ratios ranging from 4:1 to 20:1) were prepared by dissolving pH-adjusted lyophilized materials in water and infused s.c. in healthy volunteers for ≤72 hours. Frequent blood samples were collected to measure LD and CD exposure, and safety was monitored throughout the study. RESULTS: Foslevodopa/foscarbidopa (ABBV-951) demonstrates high water solubility and excellent chemical stability near physiological pH, enabling continuous s.c. infusion therapy. After s.c. infusion, a stable LD pharmacokinetic (PK) profile was maintained for ≤72 hours, and the infusion was well tolerated. INTERPRETATION: Preparation of foslevodopa and foscarbidopa enables preclinical and clinical PK, safety, and tolerability studies in support of their advancement for the treatment of PD. In phase 1 clinical trials, foslevodopa/foscarbidopa demonstrates consistent and stable LD plasma exposure, supporting further studies of this treatment as a potentially transformational option for those suffering from PD. ANN NEUROL 2021;90:52-61.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Rosebraugh M, Voight EA, Moussa EM, et al. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021. PMID: 33772855. doi:10.1002/ana.26073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。